• About
• Links
• Contact
• Sitemap

Sitemap > Breaking Research > Metabolic & Hormonal Disorders

• Assessment of single-dose benzodiazepines on insulin secretion, insulin sensitivity and glucose effectiveness in healthy volunteers: a double-blind, placebo-controlled, randomized cross-over trial [ISRCTN08745124].
• Calorie restriction promotes mammalian cell survival by inducing the SIRT1 deacetylase.
• Insulin resistance and endothelial dysfunction in type 2 diabetes patients with or without microalbuminuria.
• Is diabetes an independent risk factor for mortality after myocardial infarction? The ARIC (Atherosclerosis Risk in Communities) Surveillance Study.
• 4-Acylamino-6-arylfuro[2,3-d]pyrimidines: potent and selective glycogen synthase kinase-3 inhibitors.
• Randomized trial of effect of alendronate continuation versus discontinuation in women with low BMD: results from the Fracture Intervention Trial long-term extension.
• Risk-benefit profile for raloxifene: 4-year data From the Multiple Outcomes of Raloxifene Evaluation (MORE) randomized trial.
• Muscle-specific overexpression of CD36 reverses the insulin resistance and diabetes of MKR mice.
• A central role for inflammation in the pathogenesis of diabetic retinopathy.
• Antidiabetic effect of novel modulating peptides of G-protein-coupled kinase in experimental models of diabetes.
• Impact of diabetes mellitus on long-term outcome after unstable angina and non-ST-segment elevation myocardial infarction treated with a very early invasive strategy.
• Risk factor management in diabetic and non-diabetic patients with coronary heart disease. Findings from the EUROASPIRE I AND II surveys.
• Enhancement of early- and late-phase insulin secretion and insulin sensitivity by the combination of repaglinide and metformin in type 2 diabetes mellitus.
• Blockade of late stages of autoimmune diabetes by inhibition of the receptor for advanced glycation end products.
• Rosiglitazone improves, while Glibenclamide worsens blood pressure control in treated hypertensive diabetic and dyslipidemic subjects via modulation of insulin resistance and sympathetic activity.
• Synthesis of tetrahydronaphthyl thioureas as potent appetite suppressants.
• Comparative effects of GLP-1 and GIP on cAMP production, insulin secretion, and in vivo antidiabetic actions following substitution of Ala8/Ala2 with 2-aminobutyric acid.
• Effect of oral CCK-1 agonist GI181771X on fasting and postprandial gastric functions in healthy volunteers.
• Efficacy of pharmacotherapy for weight loss in adults with type 2 diabetes mellitus: a meta-analysis.
• Impact of diabetes and previous myocardial infarction on long-term survival: 25-year mortality follow-up of primary screenees of the Multiple Risk Factor Intervention Trial.
• Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines.
• Physical training may enhance beta-cell function in type 2 diabetes.
• Body size and breast cancer risk: findings from the European Prospective Investigation into Cancer And Nutrition (EPIC).
• Cyclic nucleotide phosphodiesterase 3A-deficient mice as a model of female infertility.
• Transgenic rescue of insulin receptor-deficient mice.
• Obese and diabetic db/db mice develop marked liver fibrosis in a model of nonalcoholic steatohepatitis: role of short-form leptin receptors and osteopontin.
• Equivalence of indapamide SR and enalapril on microalbuminuria reduction in hypertensive patients with type 2 diabetes: the NESTOR Study.
• In vitro and in vivo prevention of HIV protease inhibitor-induced insulin resistance by a novel small molecule insulin receptor activator.
• Novel substituted 4-phenyl-[1,3]dioxanes: potent and selective orexin receptor 2 (OX(2)R) antagonists.
• Rational design of potent and selective NH-linked aryl/heteroaryl cathepsin K inhibitors.
• Alpha,alpha-difluoro-beta-ketophosphonates as potent inhibitors of protein tyrosine phosphatase 1B.
• Elevation of intracavernous pressure and NO-cGMP activity by a new herbal formula in penile tissues of aged and diabetic rats.
• Atorvastatin improves diabetic dyslipidemia and increases lipoprotein lipase activity in vivo.
• Effect of atorvastatin on risk of recurrent cardiovascular events after an acute coronary syndrome associated with high soluble CD40 ligand in the Myocardial Ischemia Reduction with Aggressive Cholesterol Lowering (MIRACL) Study.
• Visceral fat in hypertension: influence on insulin resistance and beta-cell function.
• Novel 18beta-glycyrrhetinic acid analogues as potent and selective inhibitors of 11beta-hydroxysteroid dehydrogenases.
• Taurine increases glucose sensitivity of UCP2-overexpressing beta-cells by ameliorating mitochondrial metabolism.
• Tetrahydrobiopterin increases insulin sensitivity in patients with type 2 diabetes and coronary heart disease.
• Substituted 3-imidazo[1,2-a]pyridin-3-yl- 4-(1,2,3,4-tetrahydro-[1,4]diazepino-[6,7,1-hi]indol-7-yl)pyrrole-2,5-diones as highly selective and potent inhibitors of glycogen synthase kinase-3.
• A virtual screening approach to finding novel and potent antagonists at the melanin-concentrating hormone 1 receptor.
• Phenylguanidines as selective nonpeptide melanocortin-5 receptor antagonists.
• Expression of ICAM-1 by osteoblasts in healthy individuals and in patients suffering from osteoarthritis and osteoporosis.
• Acute and chronic effects of FR-149175, a beta 3-adrenergic receptor agonist, on energy expenditure in Zucker fatty rats.
• Effect of a beta-3 agonist on food intake in two strains of rats that differ in susceptibility to obesity.
• Flt3-ligand treatment prevents diabetes in NOD mice.
• Are we underestimating diabetes-related lower-extremity amputation rates? Results and benefits of the first prospective study.
• Additive effects of glucagon-like peptide 1 and pioglitazone in patients with type 2 diabetes.
• The effect of liraglutide, a long-acting glucagon-like peptide 1 derivative, on glycemic control, body composition, and 24-h energy expenditure in patients with type 2 diabetes.
• Expression levels of genes likely involved in glucose-sensing in the obese Zucker rat brain.
• NF-kappaB activation and overexpression of regulated genes in human diabetic nephropathy.
• Experimental Peptide Identification Repository (EPIR): an integrated peptide-centric platform for validation and mining of tandem mass spectrometry data.
• Cancer cachexia is regulated by selective targeting of skeletal muscle gene products.
• Characteristics of US adults with the metabolic syndrome and therapeutic implications.
• Outcomes of initiation of therapy with once-daily combination of a thiazolidinedione and a biguanide at an early stage of type 2 diabetes.
• Effects of orlistat on obesity-related diseases - a six-month randomized trial.
• In vitro and in vivo evaluation of a melamine dendrimer as a vehicle for drug delivery.
• Pregabalin for the treatment of painful diabetic peripheral neuropathy: a double-blind, placebo-controlled trial.
• Venlafaxine extended release in the treatment of painful diabetic neuropathy: a double-blind, placebo-controlled study.
• Intranasal insulin improves memory in humans.
• Novel diacylglycerol kinase inhibitor selectively suppressed an U46619-induced enhancement of mouse portal vein contraction under high glucose conditions.
• Nephroprotection in Zucker diabetic fatty rats by vasopeptidase inhibition is partly bradykinin B2 receptor dependent.
• Prior statin therapy is associated with a decreased rate of severe sepsis.
• Short-term intermittent exposure to diazoxide improves functional performance of beta-cells in a high-glucose environment.
• Impaired activation of protein kinase C-zeta by insulin and phosphatidylinositol-3,4,5-(PO4)3 in cultured preadipocyte-derived adipocytes and myotubes of obese subjects.
• Absolute risk of childhood-onset type 1 diabetes defined by human leukocyte antigen class II genotype: a population-based study in the United Kingdom.
• Liver-selective glucocorticoid antagonists: a novel treatment for type 2 diabetes.
• Identification of structurally diverse growth hormone secretagogue agonists by virtual screening and structure-activity relationship analysis of 2-formylaminoacetamide derivatives.
• Adenoviral-mediated expression of porphobilinogen deaminase in liver restores the metabolic defect in a mouse model of acute intermittent porphyria.
• A vitamin D analog down-regulates proinflammatory chemokine production by pancreatic islets inhibiting T cell recruitment and type 1 diabetes development.
• Pharmacokinetic changes of DA-8159, a new erectogenic, after intravenous and oral administration to rats with diabetes mellitus induced by streptozotocin.
• Regulation of bone mass and bone turnover by neuronal nitric oxide synthase.
• Small-molecule insulin mimetic reduces hyperglycemia and obesity in a nongenetic mouse model of type 2 diabetes.
• Small interfering RNA-induced transcriptional gene silencing in human cells.
• Insulin analogues (insulin detemir and insulin aspart) versus traditional human insulins (NPH insulin and regular human insulin) in basal-bolus therapy for patients with type 1 diabetes.
• Pancreatic islets from cyclin-dependent kinase 4/R24C (Cdk4) knockin mice have significantly increased beta cell mass and are physiologically functional, indicating that Cdk4 is a potential target for pancreatic beta cell mass regeneration in Type 1 diabetes.
• Prevention of sensory disorders in diabetic Sprague-Dawley rats by aldose reductase inhibition or treatment with ciliary neurotrophic factor.
• Albuminuria, a therapeutic target for cardiovascular protection in type 2 diabetic patients with nephropathy.
• Mimetics of caloric restriction include agonists of lipid-activated nuclear receptors.
• Nifedipine retard was as effective as angiotensin converting enzyme inhibitors in preventing cardiac events in high-risk hypertensive patients with diabetes and coronary artery disease: the Japan Multicenter Investigation for Cardiovascular Diseases-B (JMIC-B) subgroup analysis.
• Effects of telmisartan compared with eprosartan on blood pressure control, glucose metabolism and lipid profile in hypertensive, type 2 diabetic patients: a randomized, double-blind, placebo-controlled 12-month study.
• Possible role of VEGF in the progression of kidney disease in streptozotocin (STZ)-induced diabetic rats: effects of an ACE inhibitor and an angiotensin II receptor antagonist.
• GUIDE study: double-blind comparison of once-daily gliclazide MR and glimepiride in type 2 diabetic patients.
• Low-dose growth hormone and human immunodeficiency virus-associated lipodystrophy syndrome: a pilot study.
• Differential expression of 5-HT(2A) and 5-HT(2C) receptor mRNAs in mice prone, or resistant, to chronic high-fat diet-induced obesity.
• Absence of S6K1 protects against age- and diet-induced obesity while enhancing insulin sensitivity.
• Rofecoxib decreases renal injury in obese Zucker rats.
• Comparison of the pharmacological effects of a novel selective androgen receptor modulator, the 5alpha-reductase inhibitor finasteride, and the antiandrogen hydroxyflutamide in intact rats: new approach for benign prostate hyperplasia.
• Functional immunomics: microarray analysis of IgG autoantibody repertoires predicts the future response of mice to induced diabetes.
• Does albuminuria predict cardiovascular outcome on treatment with losartan versus atenolol in hypertension with left ventricular hypertrophy? A LIFE substudy.
• Long-term protection of obese Zucker rat kidneys from fibrosis and renal failure with an angiotensin-converting enzyme inhibitor/diuretic combination.
• HMG-CoA reductase inhibitors and the risk of vertebral fracture.
• Safety and efficacy of a novel salmon calcitonin (sCT) technology-based oral formulation in healthy postmenopausal women: acute and 3-month effects on biomarkers of bone turnover.
• Short- and long-term effects of interleukin-2 on weight, food intake, and hedonic mechanisms in the rat.
• Foxa2 regulates multiple pathways of insulin secretion.
• Mature high-affinity immune responses to (pro)insulin anticipate the autoimmune cascade that leads to type 1 diabetes.
• Portal infusion of a selective serotonin reuptake inhibitor enhances hepatic glucose disposal in conscious dogs.
• Dipeptide boronic acid, a novel proteasome inhibitor, prevents islet-allograft rejection.
• Prolonged glucose normalization of streptozotocin-induced diabetic mice by transplantation of rat islets coencapsulated with crosslinked hemoglobin.
• Insulin therapy for type 2 diabetes: rescue, augmentation, and replacement of beta-cell function.
• HMG-CoA reductase inhibitors prevent bone loss in patients with Type 2 diabetes mellitus.
• In vivo gene transfer to pancreatic beta cells by systemic delivery of adenoviral vectors.
• High-density lipoproteins retard the progression of atherosclerosis and favorably remodel lesions without suppressing indices of inflammation or oxidation.
• Evaluation of a novel in vitro Caco-2 hepatocyte hybrid system for predicting in vivo oral bioavailability.
• Rational design of RAR-selective ligands revealed by RARbeta crystal stucture.
• Intrasubject variability of inhaled insulin in type 1 diabetes: a comparison with subcutaneous insulin.
• M40403 prevents myocardial injury induced by acute hyperglycaemia in perfused rat heart.
• The 5-lipoxygenase pathway promotes pathogenesis of hyperlipidemia-dependent aortic aneurysm.
• Impact of changes in HbA1c, lipids and blood pressure on long-term outcomes in type 2 diabetes patients: an analysis using the CORE Diabetes Model.
• What impact would pancreatic beta-cell preservation have on life expectancy, quality-adjusted life expectancy and costs of complications in patients with type 2 diabetes? A projection using the CORE Diabetes Model.
• Synthesis of cinnamic acid derivatives and their inhibitory effects on LDL-oxidation, acyl-CoA:cholesterol acyltransferase-1 and -2 activity, and decrease of HDL-particle size.
• Discovery of potent and selective beta-homophenylalanine based dipeptidyl peptidase IV inhibitors.
• Substituted piperazines as novel dipeptidyl peptidase IV inhibitors.
• Lipid-altering changes and pleiotropic effects of atorvastatin in patients with hypercholesterolemia.
• Impact of the metabolic syndrome on mortality from coronary heart disease, cardiovascular disease, and all causes in United States adults.
• Regression of hypertensive left ventricular hypertrophy by losartan compared with atenolol: the Losartan Intervention for Endpoint Reduction in Hypertension (LIFE) trial.
• Early statin treatment in patients with acute coronary syndrome: demonstration of the beneficial effect on atherosclerotic lesions by serial volumetric intravascular ultrasound analysis during half a year after coronary event: the ESTABLISH Study.
• Diabetes, impaired fasting glucose, and development of cognitive impairment in older women.
• PREDICT modeling and in-silico screening for G-protein coupled receptors.
• Calcium channel blockers, either amlodipine or mibefradil, ameliorate renal injury in experimental diabetes.
• Is decreased libido associated with the use of HMG-CoA-reductase inhibitors?
• Type 2 diabetes mellitus contributes to cognitive decline in old age: a longitudinal population-based study.
• Cholecystokinin-induced satiety is mediated through interdependent cooperation of CCK-A and 5-HT3 receptors.
• Remission to normoalbuminuria during multifactorial treatment preserves kidney function in patients with type 2 diabetes and microalbuminuria.
• Bone marrow-derived monocyte chemoattractant protein-1 receptor CCR2 is critical in angiotensin II-induced acceleration of atherosclerosis and aneurysm formation in hypercholesterolemic mice.
• Syntaxin 4 transgenic mice exhibit enhanced insulin-mediated glucose uptake in skeletal muscle.
• Involvement of hypothalamic histamine H1 receptor in the regulation of feeding rhythm and obesity.
• Effect of intravenous infusion of exenatide (synthetic exendin-4) on glucose-dependent insulin secretion and counterregulation during hypoglycemia.
• A recombinant human glucagon-like peptide (GLP)-1-albumin protein (albugon) mimics peptidergic activation of GLP-1 receptor-dependent pathways coupled with satiety, gastrointestinal motility, and glucose homeostasis.
• Transplantation in the diabetic patient with advanced chronic kidney disease: a task force report.
• Family 2 cystatins inhibit osteoclast-mediated bone resorption in calvarial bone explants.
• Fluoxetine attenuates thermal hyperalgesia through 5-HT1/2 receptors in streptozotocin-induced diabetic mice.
• Early intensive vs a delayed conservative simvastatin strategy in patients with acute coronary syndromes: phase Z of the A to Z trial.
• The novel antiobesic HMR1426 reduces food intake without affecting energy expenditure in rats.
• N-Phenyl-4-pyrazolo[1,5-b]pyridazin-3-ylpyrimidin-2-amines as potent and selective inhibitors of glycogen synthase kinase 3 with good cellular efficacy.
• Dipeptidomimetic ketomethylene isosteres as pro-moieties for drug transport via the human intestinal di-/tripeptide transporter hPEPT1: design, synthesis, stability, and biological investigations.
• Potent and selective P2-P3 ketoamide inhibitors of cathepsin K with good pharmacokinetic properties via favorable P1', P1, and/or P3 substitutions.
• A novel anionic dendrimer for improved cellular delivery of antisense oligonucleotides.
• A randomised, placebo controlled, comparative trial of the gastrointestinal safety and efficacy of AZD3582 versus naproxen in osteoarthritis.
• Diabetes mellitus and unstable coronary artery disease: improved clinical outcome of coronary artery stenting in an era of glycoprotein IIb/IIIa inhibitors and lipid-lowering therapy.
• A selective androgen receptor modulator for hormonal male contraception.
• A novel IKKbeta inhibitor stimulates adiponectin levels and ameliorates obesity-linked insulin resistance.
• Reduction of brain injury by antithrombotic agent acutobin after middle cerebral artery ischemia/reperfusion in the hyperglycemic rat.
• Effects of glucagon-like peptide-1 on endothelial function in type 2 diabetes patients with stable coronary artery disease.
• The renal protective effects of angiotensin II receptor blockers in type 2 diabetes mellitus.
• Identification of biphenylcarboxylic acid derivatives as a novel class of bone resorption inhibitors.
• 11beta-hydroxysteroid dehydrogenase type 1 activity in lean and obese males with type 2 diabetes mellitus.
• Rapid structure-activity and selectivity analysis of kinase inhibitors by BioMAP analysis in complex human primary cell-based models.
• Structure-activity relationships of piperazinebenzylamines as potent and selective agonists of the human melanocortin-4 receptor.
• Discovery of inhibitors of human adipocyte fatty acid-binding protein, a potential type 2 diabetes target.
• Synthesis and evaluation of new hydrazide derivatives as neuropeptide Y Y5 receptor antagonists for the treatment of obesity.
• Blockade of the renin-angiotensin system decreases adipocyte size with improvement in insulin sensitivity.
• Inhibition of glycogen synthase kinase-3 represses androgen receptor activity and prostate cancer cell growth.
• Renin-angiotensin blockade attenuates cardiac myofibrillar remodelling in chronic diabetes.
• Effect of amlodipine-atorvastatin combination on fibrinolysis in hypertensive hypercholesterolemic patients with insulin resistance.
• Analgesic effect of TT-232, a heptapeptide somatostatin analogue, in acute pain models of the rat and the mouse and in streptozotocin-induced diabetic mechanical allodynia.
• Antiproteinuric effect of candesartan cilexetil in Japanese subjects with type 2 diabetes and nephropathy.
• Newly diagnosed and previously known diabetes mellitus and 1-year outcomes of acute myocardial infarction: the VALsartan In Acute myocardial iNfarcTion (VALIANT) trial.
• Catalytic domain crystal structure of protein kinase C-theta (PKCtheta).
• Use of beta-blockers and risk of fractures.
• Nonpeptidic, noncovalent inhibitors of the cysteine protease cathepsin S.
• Nonpeptide alphavbeta3 antagonists. Part 11: discovery and preclinical evaluation of potent alphavbeta3 antagonists for the prevention and treatment of osteoporosis.
• Exploring the binding mode of semicarbazide-sensitive amine oxidase/VAP-1: identification of novel substrates with insulin-like activity.
• Pharmacoeconomic challenges in the management of diabetic nephropathy.
• Intracorporal injection of hSlo cDNA restores erectile capacity in STZ-diabetic F-344 rats in vivo.
• PKC-theta knockout mice are protected from fat-induced insulin resistance.
• A pilot study on safety and pharmacokinetics of infliximab for the cancer anorexia/weight loss syndrome in non-small-cell lung cancer patients.
• Comparison of frequency of insulin resistance after coronary stenting in patients with type 2 diabetes mellitus with versus without coronary restenosis.
• Anticachectic effects of formoterol: a drug for potential treatment of muscle wasting.
• Development of glucose intolerance in male transgenic mice overexpressing human glycogen synthase kinase-3beta on a muscle-specific promoter.
• 4-Acylamino-and 4-ureidobenzamides as melanin-concentrating hormone (MCH) receptor 1 antagonists.
• Potent and selective proline derived dipeptidyl peptidase IV inhibitors.
• Synthesis of anilino-monoindolylmaleimides as potent and selective PKCbeta inhibitors.
• Synthesis and in vitro evaluation of (S)-2-([11C]methoxy)-4-[3-methyl-1-(2-piperidine-1-yl-phenyl)-butyl-carbamoyl]-benzoic acid ([11C]methoxy-repaglinide): a potential beta-cell imaging agent.
• Novel isoxazole carboxamides as growth hormone secretagogue receptor (GHS-R) antagonists.
• Piperidine-containing beta-arylpropionic acids as potent antagonists of alphavbeta3/alphavbeta5 integrins.
• Suppression of cancer cachexia by 20S,21-epoxy-resibufogenin-3-acetate-a novel nonpeptide IL-6 receptor antagonist.
• Acute IL-6 treatment increases fatty acid turnover in elderly humans in vivo and in tissue culture in vitro.
• Oral spray insulin in treatment of type 2 diabetes: a comparison of efficacy of the oral spray insulin (Oralin) with subcutaneous (SC) insulin injection, a proof of concept study.
• Novel RGD-like molecules based on the tyrosine template: design, synthesis, and biological evaluation on isolated integrins alphaVbeta3/alphaIIbbeta3 and in cellular adhesion tests.
• The impact of DeltaG on the oral bioavailability of low bioavailable therapeutic agents.
• Neuromedin U has a novel anorexigenic effect independent of the leptin signaling pathway.
• Possible novel therapy for diabetes with cell-permeable JNK-inhibitory peptide.
• Meta-analysis of the efficacy of alendronate for the prevention of hip fractures in postmenopausal women.
• Using yeast to screen for inhibitors of protein tyrosine phosphatase 1B.
• Insulin glulisine provides improved glycemic control in patients with type 2 diabetes.
• Fluvastatin enhances the inhibitory effects of a selective AT1 receptor blocker, valsartan, on atherosclerosis.
• Modulatory effect of the PDE-5 inhibitor sildenafil in diabetic neuropathy.
• Defects in adaptive energy metabolism with CNS-linked hyperactivity in PGC-1alpha null mice.
• Bis[3-(4'-substituted phenyl)prop-2-ene]disulfides as a new class of antihyperlipidemic compounds.
• 17beta-Estradiol replacement improves renal function and pathology associated with diabetic nephropathy.
• Design and synthesis of aryl diphenolic azoles as potent and selective estrogen receptor-beta ligands.
• Potent and selective ketoamide-based inhibitors of cysteine protease, cathepsin K.
• Effect of fluvastatin on renal end points in the Assessment of Lescol in Renal Transplant (ALERT) trial.
• Effects of infliximab treatment on insulin resistance in patients with rheumatoid arthritis and ankylosing spondylitis.
• Inhibition of endogenous leptin protects mice from arterial and venous thrombosis.
• Effects of angiotensin converting enzyme inhibitors and angiotensin II receptor antagonists on mortality and renal outcomes in diabetic nephropathy: systematic review.
• A novel approach to treatment of hypertension in diabetic patients - a multicenter, double-blind, randomized study comparing the efficacy of combination therapy of Eprosartan versus Ramipril with low-dose Hydrochlorothiazide and Moxonidine on blood pressure levels in patients with hypertension and associated diabetes mellitus type 2 - rationale and design [ISRCTN55725285].
• The effect of irbesartan in reducing cardiovascular risk in hypertensive type 2 diabetic patients: an observational study in 16,600 patients in primary care.
• Hepatic glucagon receptor binding and glucose-lowering in vivo by peptidyl and non-peptidyl glucagon receptor antagonists.
• Safety of rosuvastatin.
• Design and synthesis of highly potent and selective (2-arylcarbamoyl-phenoxy)-acetic acid inhibitors of aldose reductase for treatment of chronic diabetic complications.
• Comparative efficacy of hormone replacement therapy, etidronate, calcitonin, alfacalcidol, and vitamin K in postmenopausal women with osteoporosis: The Yamaguchi Osteoporosis Prevention Study.
• Effects of statins on stroke prevention in patients with and without coronary heart disease: a meta-analysis of randomized controlled trials.
• Intravenous administration of hepatocyte growth factor gene ameliorates diabetic nephropathy in mice.
• [Pharmacological and clinical profile of mitiglinide calcium hydrate (Glufast), a new insulinotropic agent with rapid onset]
• Insulin receptor substrate 2 plays a crucial role in beta cells and the hypothalamus.
• Loss of cyclin-dependent kinase inhibitors produces adipocyte hyperplasia and obesity.
• Gamma-aminobutyric acid inhibits T cell autoimmunity and the development of inflammatory responses in a mouse type 1 diabetes model.
• Electroporative transfection with KGF-1 DNA improves wound healing in a diabetic mouse model.
• Adenovirus-mediated high expression of resistin causes dyslipidemia in mice.
• Picotamide, a combined inhibitor of thromboxane A2 synthase and receptor, reduces 2-year mortality in diabetics with peripheral arterial disease: the DAVID study.
• Ertiprotafib improves glycemic control and lowers lipids via multiple mechanisms.
• Search for histamine H(3) receptor ligands with combined inhibitory potency at histamine N-methyltransferase: omega-piperidinoalkanamine derivatives.
• Comparison of the effects of telmisartan and nifedipine gastrointestinal therapeutic system on blood pressure control, glucose metabolism, and the lipid profile in patients with type 2 diabetes mellitus and mild hypertension: a 12-month, randomized, double-blind study.
• Ischaemic preconditioning does not protect the heart in obese and lean animal models of type 2 diabetes.
• Insulin therapy and colorectal cancer risk among type 2 diabetes mellitus patients.
• Isoxazole carboxylic acids as protein tyrosine phosphatase 1B (PTP1B) inhibitors.
• Ketopyrrolidines and ketoazetidines as potent dipeptidyl peptidase IV (DPP IV) inhibitors.
• Identification of neutral 4-O-alkyl quinolone nonpeptide GnRH receptor antagonists.
• Piperazinebenzylamines as potent and selective antagonists of the human melanocortin-4 receptor.
• Synergistic upregulation of low-density lipoprotein receptor activity by tamoxifen and lovastatin.
• Osteoclast differentiation is impaired in the absence of inhibitor of kappa B kinase alpha.
• Effect of anti TNFalpha therapy on arterial diameter and wall shear stress and HDL cholesterol.
• Enhanced insulin sensitivity, energy expenditure and thermogenesis in adipose-specific Pten suppression in mice.
• Inhibition of diabetic nephropathy by a decoy peptide corresponding to the "handle" region for nonproteolytic activation of prorenin.
• Constitutive activity of the melanocortin-4 receptor is maintained by its N-terminal domain and plays a role in energy homeostasis in humans.
• Double transgenic mice with type 1 diabetes mellitus develop somatic, metabolic and vascular disorders.
• Prevention and reversal of renal injury by leptin in a new mouse model of diabetic nephropathy.
• Lispro is superior to regular insulin in transient intensive insulin therapy in type 2 diabetes.
• Synthesis and protein conjugation studies of vitamin K analogues.
• 2-(4-Methoxyphenoxy)-5-nitro-N-(4-sulfamoylphenyl)benzamide activates Kir6.2/SUR1 K(ATP) channels.
• Synthesis and biological evaluation of an orally active ghrelin agonist that stimulates food consumption and adiposity in rats.
• 1,2,3,4-Tetrahydroquinoline-containing alphaVbeta3 integrin antagonists with enhanced oral bioavailability.
• Attenuation of extracellular matrix accumulation in diabetic nephropathy by the advanced glycation end product cross-link breaker ALT-711 via a protein kinase C-alpha-dependent pathway.
• Association of protein tyrosine phosphatase 1B gene polymorphisms with type 2 diabetes.
• Association of protein tyrosine phosphatase 1B gene polymorphisms with measures of glucose homeostasis in Hispanic Americans: the insulin resistance atherosclerosis study (IRAS) family study.
• Replication of an association between the lymphoid tyrosine phosphatase locus (LYP/PTPN22) with type 1 diabetes, and evidence for its role as a general autoimmunity locus.
• Effect of rosiglitazone versus insulin on the pancreatic beta-cell function of subjects with type 2 diabetes.
• Efficacy and safety of inhaled insulin (Exubera) compared with subcutaneous insulin therapy in patients with type 1 diabetes: results of a 6-month, randomized, comparative trial.
• Effects of exenatide (exendin-4) on glycemic control over 30 weeks in sulfonylurea-treated patients with type 2 diabetes.
• Anti-inflammatory effect of the ghrelin agonist growth hormone-releasing peptide-2 (GHRP-2) in arthritic rats.
• HMG-CoA reductase inhibition reverses LCAT and LDL receptor deficiencies and improves HDL in rats with chronic renal failure.
• Structural characterization and pharmacology of a potent (Cys101-Cys119, Cys110-Cys117) bicyclic agouti-related protein (AGRP) melanocortin receptor antagonist.
• Clinical implications of obesity with specific focus on cardiovascular disease: a statement for professionals from the American Heart Association Council on Nutrition, Physical Activity, and Metabolism: endorsed by the American College of Cardiology Foundation.
• Different effects of antihypertensive regimens based on fosinopril or hydrochlorothiazide with or without lipid lowering by pravastatin on progression of asymptomatic carotid atherosclerosis: principal results of PHYLLIS--a randomized double-blind trial.
• Effect of low dose atorvastatin versus diet-induced cholesterol lowering on atherosclerotic lesion progression and inflammation in apolipoprotein E*3-Leiden transgenic mice.
• Angiotensin-receptor blockade versus converting-enzyme inhibition in type 2 diabetes and nephropathy.
• Improved survival of microencapsulated islets during in vitro culture and enhanced metabolic function following transplantation.
• Synthesis and structure-activity relationships of potent 3- or 4-substituted-2-cyanopyrrolidine dipeptidyl peptidase IV inhibitors.
• The effect of WIN 55,212-2, a cannabinoid agonist, on tactile allodynia in diabetic rats.
• The regulated long-term delivery of therapeutic proteins by using antigen-specific B lymphocytes.
• Hyperinsulinaemia is associated with increased long-term mortality following acute myocardial infarction in non-diabetic patients.
• Human immunodeficiency virus protease inhibitors accumulate into cultured human adipocytes and alter expression of adipocytokines.
• Crucial role of the CCL2/CCR2 axis in neointimal hyperplasia after arterial injury in hyperlipidemic mice involves early monocyte recruitment and CCL2 presentation on platelets.
• Dual effect of angiotensin-converting enzyme inhibition on angiogenesis in type 1 diabetic mice.
• Berberine is a novel cholesterol-lowering drug working through a unique mechanism distinct from statins.
• Metabolic effects of carvedilol vs metoprolol in patients with type 2 diabetes mellitus and hypertension: a randomized controlled trial.
• The metabolic syndrome, inflammation, and risk of cognitive decline.
• Novel purine nitrile derived inhibitors of the cysteine protease cathepsin K.
• Pyrazolo[1,5-a]pyrimidines: estrogen receptor ligands possessing estrogen receptor beta antagonist activity.
• Building predictive models for protein tyrosine phosphatase 1B inhibitors based on discriminating structural features by reassembling medicinal chemistry building blocks.
• Ligand discovery using small molecule microarrays.
• Circulating levels of active ghrelin is associated with abdominal adiposity, hyperinsulinemia and insulin resistance in patients with type 2 diabetes mellitus.
• Prevalence of coronary heart disease and carotid arterial thickening in patients with the metabolic syndrome (The ARIC Study).
• 6-[2-(adamantylidene)-hydroxybenzoxazole]-O-sulfamate, a steroid sulfatase inhibitor for the treatment of androgen- and estrogen-dependent diseases.
• Tryptamine-based human beta3-adrenergic receptor agonists. Part 1: SAR studies of the 7-position of the indole ring.
• Tryptamine-based human beta3-adrenergic receptor agonists. Part 2: SAR of the methylene derivatives.
• Insulin resistance as a contributor to myocardial ischaemia independent of obstructive coronary atheroma: a role for insulin sensitisation?
• Effect of retinoic acid in experimental diabetic nephropathy.
• trans-Beta-nitrostyrene derivatives as slow-binding inhibitors of protein tyrosine phosphatases.
• Furosin, an ellagitannin, suppresses RANKL-induced osteoclast differentiation and function through inhibition of MAP kinase activation and actin ring formation.
• Roles of ATP-sensitive K+ channels as metabolic sensors: studies of Kir6.x null mice.
• Decreased sarcoplasmic reticulum activity and contractility in diabetic db/db mouse heart.
• Development of late-stage diabetic nephropathy in OVE26 diabetic mice.
• Obesity and the risk of new-onset atrial fibrillation.
• Trends in cardiovascular complications of diabetes.
• Twelve- and 52-week efficacy of the dipeptidyl peptidase IV inhibitor LAF237 in metformin-treated patients with type 2 diabetes.
• Two-year statin therapy does not alter the progression of intima-media thickness in patients with type 2 diabetes without manifest cardiovascular disease.
• Effect of pioglitazone on body composition and energy expenditure: a randomized controlled trial.
• Antidiabetic and adipogenic properties in a newly synthesized thiazolidine derivative, FPFS-410.
• Inhibition of triglyceride synthesis as a treatment strategy for obesity: lessons from DGAT1-deficient mice.
• Insulin resistance contributes to aberrant stress responses in the Tg2576 mouse model of Alzheimer's disease.
• Artificial cell microcapsule for oral delivery of live bacterial cells for therapy: design, preparation, and in-vitro characterization.
• Obesity-related leptin regulates Alzheimer's Abeta.
• The HIV-1 nucleoside reverse transcriptase inhibitors stavudine and zidovudine alter adipocyte functions in vitro.
• The effects of HIV protease inhibitors atazanavir and lopinavir/ritonavir on insulin sensitivity in HIV-seronegative healthy adults.
• The effect of PDE5 inhibition on the erectile function in streptozotocin-induced diabetic rats.
• High prevalence of peripheral arterial disease and low treatment rates in elderly primary care patients with diabetes.
• Continuum of renoprotection with losartan at all stages of type 2 diabetic nephropathy: a post hoc analysis of the RENAAL trial results.
• Efficacy and safety of pioglitazone versus metformin in patients with type 2 diabetes mellitus: a double-blind, randomized trial.
• Discovery of (2S)-N-[(1R)-2-[4-cyclohexyl-4-[[(1,1-dimethylethyl)amino]carbonyl]-1-piperidinyl]-1-[(4-fluorophenyl)methyl]-2-oxoethyl]-4-methyl-2-piperazinecarboxamide (MB243), a potent and selective melanocortin subtype-4 receptor agonist.
• Pharmacologically regulated regeneration of functional human pancreatic islets.
• Effects of pioglitazone on the components of diabetic dyslipidaemia: results of double-blind, multicentre, randomised studies.
• Inhibitory effects of mevastatin and a geranylgeranyl transferase I inhibitor (GGTI-2166) on mononuclear osteoclast formation induced by receptor activator of NF kappa B ligand (RANKL) or tumor necrosis factor-alpha (TNF-alpha).
• Metabotropic glutamate receptor mGlu5 is a mediator of appetite and energy balance in rats and mice.
• Insulin-degrading enzyme as a downstream target of insulin receptor signaling cascade: implications for Alzheimer's disease intervention.
• NOD mice have a severely impaired ability to recruit leukocytes into sites of inflammation.
• Effect of intermittent administration of human parathyroid hormone on bone mineral density and arthritis in rats with collagen-induced arthritis.
• Use of the Continuous Glucose Monitoring System to guide therapy in patients with insulin-treated diabetes: a randomized controlled trial.
• The in vitro differentiation of rat neural stem cells into an insulin-expressing phenotype.
• Prevalence of erectile dysfunction among 7689 patients with diabetes or hypertension, or both.
• The diabetes-linked transcription factor PAX4 promotes {beta}-cell proliferation and survival in rat and human islets.
• Pregabalin relieves symptoms of painful diabetic neuropathy: a randomized controlled trial.
• Synchronized infection of cell cultures by magnetically controlled virus.
• Chalcones as potent tyrosinase inhibitors: the importance of a 2,4-substituted resorcinol moiety.
• Loss of pain perception in diabetes is dependent on a receptor of the immunoglobulin superfamily.
• Meta-analysis of short-acting insulin analogues in adult patients with type 1 diabetes: continuous subcutaneous insulin infusion versus injection therapy.
• Impact of diabetes mellitus on the severity of erectile dysfunction and response to treatment: analysis of data from tadalafil clinical trials.
• Discovery of a novel, potent and selective human beta3-adrenergic receptor agonist.
• Benzoyl 2-methyl indoles as selective PPARgamma modulators.
• 3D QSAR studies on GSK-3 inhibition by aloisines.
• Potent Kv1.3 inhibitors from correolide-modification of the C18 position.
• 5-Chloroindoloyl glycine amide inhibitors of glycogen phosphorylase: synthesis, in vitro, in vivo, and X-ray crystallographic characterization.
• Characterization and regulation of the rat and human ghrelin promoters.
• Inhibition of dipeptidyl peptidase-4 augments insulin secretion in response to exogenously administered glucagon-like peptide-1, glucose-dependent insulinotropic polypeptide, pituitary adenylate cyclase-activating polypeptide, and gastrin-releasing peptide in mice.
• Visfatin: a protein secreted by visceral fat that mimics the effects of insulin.
• The efficacy, side-effects and continuation rates in women with symptomatic endometriosis undergoing treatment with an intra-uterine administered progestogen (levonorgestrel): a 3 year follow-up.
• Pharmacological properties of ABT-239 [4-(2-{2-[(2R)-2-Methylpyrrolidinyl]ethyl}-benzofuran-5-yl)benzonitrile]: II. Neurophysiological characterization and broad preclinical efficacy in cognition and schizophrenia of a potent and selective histamine H3 receptor antagonist.
• Spontaneous osteoclast formation from peripheral blood mononuclear cells in postmenopausal osteoporosis.
• Smooth muscle cell expression of a constitutive active form of human Rac 1 accelerates cutaneous wound repair.
• 4-{(2R)-[3-Aminopropionylamido]-3-(2,4-dichlorophenyl)propionyl}-1-{2-[(2-thienyl)ethylaminomethyl]phenyl}piperazine as a potent and selective melanocortin-4 receptor antagonist--design, synthesis, and characterization.
• RSK4 and PAK5 are novel candidate genes in diabetic rat kidney and brain.
• Anuroctoxin, a new scorpion toxin of the alpha-KTx 6 subfamily, is highly selective for Kv1.3 over IKCa1 ion channels of human T lymphocytes.
• Increased glucocorticoid receptor and 11{beta}-hydroxysteroid dehydrogenase type 1 expression in hepatocytes may contribute to the phenotype of type 2 diabetes in db/db mice.
• Enhanced hypothalamic AMP-activated protein kinase activity contributes to hyperphagia in diabetic rats.
• {beta}-Cell function following human islet transplantation for type 1 diabetes.
• Nuclear factor-{kappa}B activity in {beta}-cells is required for glucose-stimulated insulin secretion.
• Impairment of host resistance to Listeria monocytogenes infection in liver of db/db and ob/ob mice.
• Decreased expression of pigment epithelium-derived factor is involved in the pathogenesis of diabetic nephropathy.
• Development of a long-acting insulin analog using albumin fusion technology.
• Randomized controlled clinical trial of glargine versus ultralente insulin in the treatment of type 1 diabetes.
• A two-center randomized controlled feasibility trial of insulin pump therapy in young children with diabetes.
• Antidiabetic drugs and heart failure risk in patients with type 2 diabetes in the U.K. primary care setting.
• Metabolic syndrome among HIV-infected patients: prevalence, characteristics, and related factors.
• Foxa2 regulates lipid metabolism and ketogenesis in the liver during fasting and in diabetes.
• In vitro generation of insulin-producing beta cells from adult exocrine pancreatic cells.
• A selective estrogen receptor-beta agonist causes lesion regression in an experimentally induced model of endometriosis.
• The effect of aging on the skeletal response to intermittent treatment with parathyroid hormone.
• Free fatty acids regulate gut incretin glucagon-like peptide-1 secretion through GPR120.
• SC-19220, antagonist of prostaglandin E2 receptor EP1, inhibits osteoclastogenesis by RANKL.
• Effect of thiazolidinedione treatment on progression of subclinical atherosclerosis in premenopausal women at high risk for type 2 diabetes.
• Imatinib attenuates diabetic nephropathy in apolipoprotein E-knockout mice.
• Improvements in lipoatrophy, mitochondrial DNA levels and fat apoptosis after replacing stavudine with abacavir or zidovudine.
• The 12-month efficacy and safety of insulin detemir and NPH insulin in basal-bolus therapy for the treatment of type 1 diabetes.
• Adherence with osteoporosis practice guidelines: a multilevel analysis of patient, physician, and practice setting characteristics.
• Glucose metabolism in patients with schizophrenia treated with atypical antipsychotic agents: a frequently sampled intravenous glucose tolerance test and minimal model analysis.
• PKClambda regulates glucose-induced insulin secretion through modulation of gene expression in pancreatic beta cells.
• CaV2.3 calcium channels control second-phase insulin release.
• Retinopathy and risk of congestive heart failure.
• (2R)-4-oxo-4-[3-(trifluoromethyl)-5,6-dihydro[1,2,4]triazolo[4,3-a]pyrazin-7(8H)-yl]-1-(2,4,5-trifluorophenyl)butan-2-amine: a potent, orally active dipeptidyl peptidase IV inhibitor for the treatment of type 2 diabetes.
• Discovery of corticotropin releasing factor 2 receptor selective sauvagine analogues for treatment of skeletal muscle atrophy.
• Statin therapy, LDL cholesterol, C-reactive protein, and coronary artery disease.
• Pancreatic beta-cell lipoprotein lipase independently regulates islet glucose metabolism and normal insulin secretion.
• A novel calcium-sensing receptor antagonist transiently stimulates parathyroid hormone secretion in vivo.
• 1,25-Dihydroxyvitamin D3 modulates expression of chemokines and cytokines in pancreatic islets: implications for prevention of diabetes in nonobese diabetic mice.
• Role of meltrin {alpha} (ADAM12) in obesity induced by high- fat diet.
• Impaired endothelium-dependent responses and enhanced influence of Rho-kinase in cerebral arterioles in type II diabetes.
• Recombinant adeno-associated virus vector expressing angiostatin inhibits preretinal neovascularization in adult rats.
• Results of a randomized, double-blind, placebo-controlled study administering glimepiride to patients with type 2 diabetes mellitus inadequately controlled with rosiglitazone monotherapy.
• Nur77 regulates lipolysis in skeletal muscle cells. Evidence for cross-talk between the beta-adrenergic and an orphan nuclear hormone receptor pathway.
• Association between hormone replacement therapy and subsequent stroke: a meta-analysis.
• Phase II study of transdermal estradiol in androgen-independent prostate carcinoma.
• The anti-obesity effect of rimonabant is associated with an improved serum lipid profile.
• Insulin detemir used in basal-bolus therapy in people with type 1 diabetes is associated with a lower risk of nocturnal hypoglycaemia and less weight gain over 12 months in comparison to NPH insulin.
• Efficacy and safety of ezetimibe co-administered with simvastatin in thiazolidinedione-treated type 2 diabetic patients.
• Engineered beta-cells secreting dipeptidyl peptidase IV-resistant glucagon-like peptide-1 show enhanced glucose-responsiveness.
• Statin use and survival outcomes in elderly patients with heart failure.
• Protective effects of 6-ethyl chenodeoxycholic acid, a farnesoid X receptor ligand, in estrogen-induced cholestasis.
• Trends and determinants of antiresorptive drug use for osteoporosis among elderly women.
• Temporary angiotensin II blockade at the prediabetic stage attenuates the development of renal injury in type 2 diabetic rats.
• Caloric restriction attenuates beta-amyloid neuropathology in a mouse model of Alzheimer's disease.
• Lipodystrophy in patients with HIV-1 infection: effect of stopping protease inhibitors on TNF-alpha and TNF-receptor levels, and on metabolic parameters.
• Antiretroviral drugs with adverse effects on adipocyte lipid metabolism and survival alter the expression and secretion of proinflammatory cytokines and adiponectin in vitro.
• Prevalence of the metabolic syndrome using the Third Report of the National Cholesterol Educational Program Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (ATP III) and the modified ATP III definitions for Japanese and Mongolians.
• Synthesis and biological activity of sulphostin analogues, novel dipeptidyl peptidase IV inhibitors.
• Discovery of 1,7-cyclized indoles as a new class of potent and highly selective human beta3-adrenergic receptor agonists with high cell permeability.
• The vascular effects of doxazosin in hypertension complicated by metabolic syndrome.
• Absence of the lipid phosphatase SHIP2 confers resistance to dietary obesity.
• Estrogenic restoration of functional pancreatic islet cytoarchitecture in diabetes (db/db) mutant C57BL/KsJ mice: relationship to estradiol localization, systemic glycemia, and persistent hyperinsulinemia.
• Double-blind, placebo-controlled trial of pirfenidone in patients with idiopathic pulmonary fibrosis.
• Role of the intestinal tight junction modulator zonulin in the pathogenesis of type I diabetes in BB diabetic-prone rats.
• Reduction of PTP1B by RNAi upregulates the activity of insulin controlled fatty acid synthase promoter.
• The cost-effectiveness of lifestyle modification or metformin in preventing type 2 diabetes in adults with impaired glucose tolerance.
• A new drug carrier, Nalpha-deoxycholyl-L: -lysyl-methylester, for enhancing insulin absorption in the intestine.
• Development of an automated protein-tyrosine phosphatase 1B inhibition assay and the screening of putative insulin-enhancing vanadium(IV) and zinc(II) complexes.
• Identification of 2-(4-benzyloxyphenyl)-N- [1-(2-pyrrolidin-1-yl-ethyl)-1H-indazol-6-yl]acetamide, an orally efficacious melanin-concentrating hormone receptor 1 antagonist for the treatment of obesity.
• Synthesis and evaluation of (pyridylmethylene)tetrahydronaphthalenes/-indanes and structurally modified derivatives: potent and selective inhibitors of aldosterone synthase.
• Endocrinological properties of two novel nonsteroidal progesterone receptor modulators, CP8816 and CP8863.
• Functional selectivity of melanocortin 4 receptor peptide and nonpeptide agonists: evidence for ligand-specific conformational states.
• Nutrient control of glucose homeostasis through a complex of PGC-1alpha and SIRT1.
• Hydroxymethylglutaryl-coenzyme A reductase inhibitors and osteoporosis: a meta-analysis.
• Design, synthesis, and biological activity of novel PPARgamma ligands based on rosiglitazone and 15d-PGJ2.
• Novel and potent NPY5 receptor antagonists derived from virtual screening and iterative parallel chemistry design.
• Melanocortin subtype-4 receptor agonists containing a piperazine core with substituted aryl sulfonamides.
• Synthesis and activity of oleanolic acid derivatives, a novel class of inhibitors of osteoclast formation.
• Improvement of metabolic state in an animal model of nutrition-dependent type 2 diabetes following treatment with S 23521, a new glucagon-like peptide 1 (GLP-1) analogue.
• The molecular scaffold Gab2 is a crucial component of RANK signaling and osteoclastogenesis.
• Association between a variation in the phosphodiesterase 4D gene and bone mineral density.
• Insulin sensitivity and endothelial function in hypertension: a comparison of temocapril and candesartan.
• An insulin-response element-binding protein that ameliorates hyperglycemia in diabetes.
• Engineering of vault nanocapsules with enzymatic and fluorescent properties.
• Thalidomide in the treatment of cancer cachexia: a randomised placebo controlled trial.
• Fenofibrate reduces progression to microalbuminuria over 3 years in a placebo-controlled study in type 2 diabetes: results from the Diabetes Atherosclerosis Intervention Study (DAIS).
• Insulin protects against amyloid beta-peptide toxicity in brain mitochondria of diabetic rats.
• Is bortezomib, a proteasome inhibitor, effective in treating cancer-associated weight loss? Preliminary results from the North Central Cancer Treatment Group.
• Prevention of obesity in mice by antisense oligonucleotide inhibitors of stearoyl-CoA desaturase-1.
• Angiopoietin-related growth factor antagonizes obesity and insulin resistance.
• Tetrahydroisoquinoline 1-carboxamides as growth hormone secretagogues.
• Novel and potent cyclic cyanamide-based cathepsin K inhibitors.
• Structure-activity relationship studies on tetralin carboxamide growth hormone secretagogue receptor antagonists.
• Feeding responses to a melanocortin agonist and antagonist in obesity induced by a palatable high-fat diet.
• In silico ADME modelling: prediction models for blood-brain barrier permeation using a systematic variable selection method.
• Efficacy and safety of the coadministration of ezetimibe with fenofibrate in patients with mixed hyperlipidaemia.
• Hepatic glucocorticoid receptor antagonism is sufficient to reduce elevated hepatic glucose output and improve glucose control in animal models of type 2 diabetes.
• Inhibition of growth of experimental human endometrial cancer by an antagonist of growth hormone-releasing hormone.
• Target-directed proteolysis at the ribosome.
• Novel human neuropeptide Y Y5 receptor antagonists for the treatment of obesity. Synthesis and biological evaluation of pyridine hydrazide derivatives.
• Twice-daily pre-mixed insulin rather than basal insulin therapy alone results in better overall glycaemic control in patients with Type 2 diabetes.
• A long-term comparison of pioglitazone and gliclazide in patients with Type 2 diabetes mellitus: a randomized, double-blind, parallel-group comparison trial.
• Reduced cardiovascular morbidity and mortality associated with metformin use in subjects with Type 2 diabetes.
• Biphasic insulin aspart compared to biphasic human insulin reduces postprandial hyperlipidemia in patients with Type 2 diabetes.
• Effects of KR-32570, a new Na+/H+ exchanger inhibitor, on functional and metabolic impairments produced by global ischemia and reperfusion in the perfused rat heart.
• Metabolic syndrome and risk of restenosis in patients undergoing percutaneous coronary intervention.
• Effect of sibutramine on weight management and metabolic control in type 2 diabetes: a meta-analysis of clinical studies.
• Reduced hypoglycemia risk with insulin glargine: a meta-analysis comparing insulin glargine with human NPH insulin in type 2 diabetes.
• Deletion of the angiotensin type 2 receptor (AT2R) reduces adipose cell size and protects from diet-induced obesity and insulin resistance.
• Adipocyte-specific glucocorticoid inactivation protects against diet-induced obesity.
• Apolipoprotein M is required for prebeta-HDL formation and cholesterol efflux to HDL and protects against atherosclerosis.
• Antipsychotic drug-induced weight gain: development of an animal model.
• In vivo imaging of oxidative stress in the kidney of diabetic mice and its normalization by angiotensin II type 1 receptor blocker.
• Identification of parathyroid hormone-regulated proteins in mouse bone marrow cells by proteomics.
• Prevalence of Vitamin D inadequacy among postmenopausal North American women receiving osteoporosis therapy.
• Parathyroid hormone-related protein (PTHrP) as a causative factor of cancer-associated wasting: possible involvement of PTHrP in the repression of locomotor activity in rats bearing human tumor xenografts.
• Discovery of a novel series of peroxisome proliferator-activated receptor alpha/gamma dual agonists for the treatment of type 2 diabetes and dyslipidemia.
• Discovery of bicycloalkyl urea melanin concentrating hormone receptor antagonists: orally efficacious antiobesity therapeutics.
• High-throughput lipophilicity measurement with immobilized artificial membranes.
• Role of hypothalamic 5'-AMP-activated protein kinase in the regulation of food intake and energy homeostasis.
• 2-Piperazinecarboxamides as potent and selective melanocortin subtype-4 receptor agonists.
• Discovery, synthesis and biological evaluation of novel glucokinase activators.
• Synthesis and in vivo antihyperglycemic activity of 5-(1H-pyrazol-3-yl)methyl-1H-tetrazoles.
• Change in body mass index and its impact on blood pressure: a prospective population study.
• Effects of sibutramine on abdominal fat mass, insulin resistance and blood pressure in obese hypertensive patients.
• Antiobesity effect of a melanin-concentrating hormone 1 receptor antagonist in diet-induced obese mice.
• Relief of painful diabetic peripheral neuropathy with pregabalin: a randomized, placebo-controlled trial.
• Analysis of gene expression profiles in insulin-sensitive tissues from pre-diabetic and diabetic Zucker diabetic fatty rats.
• Deletion of Gab1 in the liver leads to enhanced glucose tolerance and improved hepatic insulin action.
• Simvastatin reduced ischemic brain injury and perfusion deficits in an embolic model of stroke.
• Inhibition of appetite by nasal leptin administration in rats.
• Novel and potent 17beta-hydroxysteroid dehydrogenase type 1 inhibitors.
• Nonoxynol-9 induces apoptosis of endometrial explants by both caspase-dependent and -independent apoptotic pathways.
• Albumin activates ERK via EGF receptor in human renal epithelial cells.
• Insulin resistance in men with treated hypertension at increased risk for cardiovascular disease: results of a 3-year study.
• PPARgamma in endothelial cells influences high fat diet-induced hypertension.
• LXRbeta is required for adipocyte growth, glucose homeostasis, and beta cell function.
• A peroxisome proliferator-activated receptor alpha/gamma dual agonist with a unique in vitro profile and potent glucose and lipid effects in rodent models of type 2 diabetes and dyslipidemia.
• Deletion of PPARgamma in adipose tissues of mice protects against high fat diet-induced obesity and insulin resistance.
• Therapeutic actions of an insulin receptor activator and a novel peroxisome proliferator-activated receptor gamma agonist in the spontaneously hypertensive obese rat model of metabolic syndrome X.
• Amyloid beta protein immunotherapy neutralizes Abeta oligomers that disrupt synaptic plasticity in vivo.
• Effects of the cannabinoid-1 receptor blocker rimonabant on weight reduction and cardiovascular risk factors in overweight patients: 1-year experience from the RIO-Europe study.
• Outcomes with the polymer-based paclitaxel-eluting TAXUS stent in patients with diabetes mellitus: the TAXUS-IV trial.
• Dipeptidyl peptidase IV inhibitors derived from beta-aminoacylpiperidines bearing a fused thiazole, oxazole, isoxazole, or pyrazole.
• Benzimidazoles as non-peptide luteinizing hormone-releasing hormone (LHRH) antagonists. Part 3: Discovery of 1-(1H-benzimidazol-5-yl)-3-tert-butylurea derivatives.
• The IkappaB kinase is a key factor in triggering influenza A virus-induced inflammatory cytokine production in airway epithelial cells.
• A-425619 [1-isoquinolin-5-yl-3-(4-trifluoromethyl-benzyl)-urea], a novel transient receptor potential type V1 receptor antagonist, relieves pathophysiological pain associated with inflammation and tissue injury in rats.
• The ATP-sensitive potassium channel blocker glibenclamide prevents renal ischemia/reperfusion injury in rats.
• Effects of NADPH oxidase inhibitor in diabetic nephropathy.
• Pharmacological and pharmacokinetic study of olmesartan medoxomil in animal diabetic retinopathy models.
• Excess deaths associated with underweight, overweight, and obesity.
• Paroxetine Controlled Release for Premenstrual Dysphoric Disorder: Remission Analysis Following a Randomized, Double-Blind, Placebo-Controlled Trial.
• Effects of the PPARgamma agonist pioglitazone on lipoprotein metabolism in patients with type 2 diabetes mellitus.
• Activation of hypothalamic ATP-sensitive K+ channels by the aminoguanidine carboxylate BVT.12777.
• Inhibition of dipeptidyl peptidase IV activity by oral metformin in Type 2 diabetes.
• Influence of acute upper respiratory tract infection on the absorption of inhaled insulin using the AERx insulin Diabetes Management System.
• Pioglitazone can ameliorate insulin resistance in low-dose streptozotocin and high sucrose-fat diet induced obese rats.
• In vivo fragmentation of heparan sulfate by heparanase overexpression renders mice resistant to amyloid protein A amyloidosis.
• Protein kinase Cbeta inhibition attenuates osteopontin expression, macrophage recruitment, and tubulointerstitial injury in advanced experimental diabetic nephropathy.
• An integral role for heme oxygenase-1 and carbon monoxide in maintaining peripheral tolerance by CD4+CD25+ regulatory T cells.
• Targeted delivery of the ErbB2/HER2 tumor antigen to professional APCs results in effective antitumor immunity.
• Novel fibrogenic pathways are activated in response to endothelial apoptosis: implications in the pathophysiology of systemic sclerosis.
• Effect of pramlintide on satiety and food intake in obese subjects and subjects with type 2 diabetes.
• The inhibition of RANKL causes greater suppression of bone resorption and hypercalcemia compared with bisphosphonates in two models of humoral hypercalcemia of malignancy.
• Interleukin-6 depletion selectively improves hepatic insulin action in obesity.
• Hypothalamic K(ATP) channels control hepatic glucose production.
• Pioglitazone in a subgroup of patients with type 2 diabetes meeting the criteria for metabolic syndrome.
• Inhibitory effects of antipsychotics on carbachol-enhanced insulin secretion from perifused rat islets: role of muscarinic antagonism in antipsychotic-induced diabetes and hyperglycemia.
• Immunomodulatory activities of small host defense peptides.
• Time-action profile of inhaled insulin in comparison with subcutaneously injected insulin lispro and regular human insulin.
• Effects of exenatide (exendin-4) on glycemic control over 30 weeks in patients with type 2 diabetes treated with metformin and a sulfonylurea.
• Effects of exenatide (exendin-4) on glycemic control and weight over 30 weeks in metformin-treated patients with type 2 diabetes.
• Reduction in cardiovascular events with atorvastatin in 2,532 patients with type 2 diabetes: Anglo-Scandinavian Cardiac Outcomes Trial--lipid-lowering arm (ASCOT-LLA).
• The effect of vitamin K2 on bone metabolism in aged female rats.
• Discovery of a beta-MSH-derived MC-4R selective agonist.
• Discovery of 3-[(4,5,7-trifluorobenzothiazol-2-yl)methyl]indole-N-acetic acid (lidorestat) and congeners as highly potent and selective inhibitors of aldose reductase for treatment of chronic diabetic complications.
• Sensitization and translocation of TRPV1 by insulin and IGF-I.
• Establishment of robust functional assays for the characterization of neuropeptide Y (NPY) receptors: identification of 3-(5-benzoyl-thiazol-2-ylamino)-benzonitrile as selective NPY type 5 receptor antagonist.
• Intercellular adhesion molecule-1 deficiency is protective against nephropathy in type 2 diabetic db/db mice.
• Factors predicting the development of metabolic syndrome and type II diabetes against a background of hypertension.
• The effect of perindopril on cardiovascular morbidity and mortality in patients with diabetes in the EUROPA study: results from the PERSUADE substudy.
• Spinal orexin-1 receptors mediate anti-hyperalgesic effects of intrathecally-administered orexins in diabetic neuropathic pain model rats.
• Selective PPARgamma modulators with improved pharmacological profiles.
• 1-((S)-gamma-substituted prolyl)-(S)-2-cyanopyrrolidine as a novel series of highly potent DPP-IV inhibitors.
• Structure-based design of protein tyrosine phosphatase-1B inhibitors.
• Discovery of potent and selective phenylalanine based dipeptidyl peptidase IV inhibitors.
• A potent and selective nonpeptide antagonist of the melanocortin-4 receptor induces food intake in satiated mice.
• Discovery of 4-(dimethylamino)quinazolines as potent and selective antagonists for the melanin-concentrating hormone receptor 1.
• Design and synthesis of novel diphenacoum-derived, conformation-restricted vitamin K 2,3-epoxide reductase inhibitors.
• A double-blind, placebo-controlled trial of sibutramine for olanzapine-associated weight gain.
• Hypoglycemic effects of turmeric (Curcuma longa L. rhizomes) on genetically diabetic KK-Ay mice.
• Hyperglycaemia increases dipeptidyl peptidase IV activity in diabetes mellitus.
• Altered adipokine response in murine 3T3-F442A adipocytes treated with protease inhibitors and nucleoside reverse transcriptase inhibitors.
• Crystal structure of murine 11 beta-hydroxysteroid dehydrogenase 1: an important therapeutic target for diabetes.
• The role of protein-tyrosine phosphatase 1B in integrin signaling.
• Biological activity assessment of a novel contraceptive antimicrobial agent.
• Effect of atorvastatin and irbesartan, alone and in combination, on postprandial endothelial dysfunction, oxidative stress, and inflammation in type 2 diabetic patients.
• Preventing renal complications in diabetic patients: the Diabetics Exposed to Telmisartan And enalaprIL (DETAIL) study.
• Osteopenia and impaired fracture healing in aged EP4 receptor knockout mice.
• Antitumoral actions of the anti-obesity drug orlistat (XenicalTM) in breast cancer cells: blockade of cell cycle progression, promotion of apoptotic cell death and PEA3-mediated transcriptional repression of Her2/neu (erbB-2) oncogene.
• 17 Beta-estradiol improves survival in male mice with cardiomyopathy induced by cardiac-specific tumor necrosis factor-alpha overexpression.
• Synthesis of a novel potent cyclic peptide MC4-ligand by ring-closing metathesis.
• Relation of the metabolic syndrome to calcified atherosclerotic plaque in the coronary arteries and aorta.
• Peripheral angioplasty as the first-choice revascularization procedure in diabetic patients with critical limb ischemia: prospective study of 993 consecutive patients hospitalized and followed between 1999 and 2003.
• Attenuation of diet-induced weight gain and adiposity through increased energy expenditure in mice lacking angiotensin II type 1a receptor.
• Prevention and cure of autoimmune diabetes in nonobese diabetic mice by continuous administration of FTY720.
• Effect of pioglitazone on metabolic syndrome risk factors: results of double-blind, multicenter, randomized clinical trials.
• The association of heart failure with insulin resistance and the development of type 2 diabetes.
• Pioglitazone decreases carotid intima-media thickness independently of glycemic control in patients with type 2 diabetes mellitus: results from a controlled randomized study.
• Vascular and metabolic effects of combined therapy with ramipril and simvastatin in patients with type 2 diabetes.
• Leptin treatment induces loss of bone marrow adipocytes and increases bone formation in leptin-deficient ob/ob mice.
• Simvastatin regulates myocardial cytokine expression and improves ventricular remodeling in rats after acute myocardial infarction.
• COX-2 up-regulation and vascular smooth muscle contractile hyperreactivity in spontaneous diabetic db/db mice.
• Anabolic growth hormone action improves submaximal measures of physical performance in patients with HIV-associated wasting.
• PPARgamma agonists exert antifibrotic effects in renal tubular cells exposed to high glucose.
• Type-II diabetes and pancreatic cancer: a meta-analysis of 36 studies.
• Effect of plasminogen activator inhibitor-1 deficiency on nutritionally-induced obesity in mice.
• Relation of insulin resistance and left ventricular function and structure in non-diabetic patients with essential hypertension.
• XIAP overexpression in islet beta-cells enhances engraftment and minimizes hypoxia-reperfusion injury.
• Subcutaneous ghrelin enhances acute food intake in malnourished patients who receive maintenance peritoneal dialysis: a randomized, placebo-controlled trial.
• Expanded T cells from pancreatic lymph nodes of type 1 diabetic subjects recognize an insulin epitope.
• 4,5-Disubstituted cis-pyrrolidinones as inhibitors of type II 17beta-hydroxysteroid dehydrogenase. Part 2. SAR.
• Inhibition of dipeptidyl peptidase IV by novel inhibitors with pyrazolidine scaffold.
• Effect of a selective OX1R antagonist on food intake and body weight in two strains of rats that differ in susceptibility to dietary-induced obesity.
• Hologram quantitative structure-activity relationships for a series of farnesoid X receptor activators.
• Prediction of preadipocyte differentiation by gene expression reveals role of insulin receptor substrates and necdin.
• Effect of valsartan on monocyte/endothelial cell activation markers and adiponectin in hypertensive patients with type 2 diabetes mellitus.
• Macrophage-specific expression of group IIA sPLA2 results in accelerated atherogenesis by increasing oxidative stress.
• Negative metabolic effects of cGMP are enhanced in obese rat hearts.
• Cannabinoids and ghrelin have both central and peripheral metabolic and cardiac effects via AMP-activated protein kinase.
• Cell-replacement therapy for diabetes: Generating functional insulin-producing tissue from adult human liver cells.
• Proteome of H-411E (liver) cells exposed to insulin and tumor necrosis factor-alpha: analysis of proteins involved in insulin resistance.
• FGF-21 as a novel metabolic regulator.
• Discovery of potent and selective orally bioavailable beta-substituted phenylalanine derived dipeptidyl peptidase IV inhibitors.
• Antibody mediated in vivo delivery of small interfering RNAs via cell-surface receptors.
• Regulation of bone mass, bone loss and osteoclast activity by cannabinoid receptors.
• Prevention of diabetes by manipulation of anti-IGRP autoimmunity: high efficiency of a low-affinity peptide.
• Effect of PK11195, a peripheral benzodiazepine receptor agonist, on insulinoma cell death and insulin secretion.
• Cholesterol-lowering effects of rosuvastatin compared with atorvastatin in patients with type 2 diabetes -- CORALL study.
• Risk factors for peripheral arterial disease incidence in persons with diabetes: the Atherosclerosis Risk in Communities (ARIC) Study.
• "Vasocrine" signalling from perivascular fat: a mechanism linking insulin resistance to vascular disease.
• Synthesis and evaluation of urea-based indazoles as melanin-concentrating hormone receptor 1 antagonists for the treatment of obesity.
• Discovery and development of dimeric podocarpic acid leads as potent agonists of liver X receptor with HDL cholesterol raising activity in mice and hamsters.
• Synthesis and biological evaluation of sulfonamidooxazoles and beta-keto sulfones: selective inhibitors of 11beta-hydroxysteroid dehydrogenase type I.
• Novel 2-N,N-dimethylaminomethyl-2,3,3a,12b-tetrahydrodibenzo[b,f]furo[2,3-d]oxepin derivatives displaying combined norepinephrine reuptake inhibition and 5-HT2A/2C receptor antagonism.
• MB06322 (CS-917): A potent and selective inhibitor of fructose 1,6-bisphosphatase for controlling gluconeogenesis in type 2 diabetes.
• Alpha-lipoic acid increases insulin sensitivity by activating AMPK in skeletal muscle.
• The Ins2Akita mouse as a model of early retinal complications in diabetes.
• Diabetes-induced renal vascular dysfunction is normalized by inhibition of epidermal growth factor receptor tyrosine kinase.
• Dose-response for glycaemic and metabolic changes 28 days after single injection of long-acting release exenatide in diabetic fatty Zucker rats.
• Protective effects of bendazac lysine on early experimental diabetic nephropathy in rats.
• Additive antiproteinuric effect of pentoxifylline in patients with type 2 diabetes under angiotensin II receptor blockade: a short-term, randomized, controlled trial.
• Peptide S is a novel potent inhibitor of voluntary and fast-induced food intake in rats.
• A single course of anti-CD3 monoclonal antibody hOKT3gamma1(Ala-Ala) results in improvement in C-peptide responses and clinical parameters for at least 2 years after onset of type 1 diabetes.
• Reduction of hepatic and adipose tissue glucocorticoid receptor expression with antisense oligonucleotides improves hyperglycemia and hyperlipidemia in diabetic rodents without causing systemic glucocorticoid antagonism.
• Structural bioinformatics-based design of selective, irreversible kinase inhibitors.
• A prospective study of soluble tumor necrosis factor-alpha receptor II (sTNF-RII) and risk of coronary heart disease among women with type 2 diabetes.
• The effect of DA-8159, a novel PDE5 inhibitor, on erectile function in the rat model of hypercholesterolemic erectile dysfunction.
• A novel, long-acting agonist of glucose-dependent insulinotropic polypeptide suitable for once-daily administration in type 2 diabetes.
• DPP IV inhibitor blocks mescaline-induced scratching and amphetamine-induced hyperactivity in mice.
• Adrenomedullin: a new target for the design of small molecule modulators with promising pharmacological activities.
• Duloxetine vs. placebo in patients with painful diabetic neuropathy.
• Glutamic acid analogues as potent dipeptidyl peptidase IV and 8 inhibitors.
• Adipose-specific overexpression of GLUT4 reverses insulin resistance and diabetes in mice lacking GLUT4 selectively in muscle.
• Cachexia in chronic kidney disease: a link to defective central nervous system control of appetite.
• Hydroxymethylglutaryl co-enzyme A reductase inhibition attenuates endotoxin-mediated inflammatory responses.
• Comparison of rosuvastatin and atorvastatin for lipid lowering in patients with type 2 diabetes mellitus: results from the URANUS study.
• Novel regulatory roles for protein phosphatase-2A in the islet beta cell.
• Combined effects of oleoyl-estrone and a beta3-adrenergic agonist (CL316,243) on lipid stores of diet-induced overweight male Wistar rats.
• Construction of a virtual combinatorial library using SMILES strings to discover potential structure-diverse PPAR modulators.
• Synthesis and biological evaluation of novel bisphosphonates with dual activities on bone in vitro.
• The PPARdelta agonist GW0742X reduces atherosclerosis in LDLR(-/-) mice.
• Dysregulation of the endothelial nitric oxide synthase-soluble guanylate cyclase pathway is normalized by insulin in the aorta of diabetic rat.
• D-4F induces heme oxygenase-1 and extracellular superoxide dismutase, decreases endothelial cell sloughing, and improves vascular reactivity in rat model of diabetes.
• High-throughput screening of interactions between G protein-coupled receptors and ligands using confocal optics microscopy.
• Effects of STZ-induced diabetes and its treatment with vanadyl sulphate on cyclosporine A-induced nephrotoxicity in rats.
• Metabolic and cellular plasticity in white adipose tissue II: role of peroxisome proliferator-activated receptor-alpha.
• Metabolic and cellular plasticity in white adipose tissue I: effects of beta3-adrenergic receptor activation.
• Inhibition of membrane type-1 matrix metalloproteinase by cancer drugs interferes with the homing of diabetogenic T cells into the pancreas.
• Stem cell division is regulated by the microRNA pathway.
• A database of recombinant viruses and recombinant viral vectors available from the RIKEN DNA bank.
• Effect of HMG-CoA-reductase inhibitors on survival in type 2 diabetes patients with end stage diabetic nephropathy.
• Recombinant leptin promotes atherosclerosis and thrombosis in apolipoprotein E-deficient mice.
• Roles of PPAR delta in lipid absorption and metabolism: a new target for the treatment of type 2 diabetes.
• Hepatocyte growth factor is constitutively produced by donor-derived bone marrow cells and promotes regeneration of pancreatic beta-cells.
• Synthesis and structure-activity relationships of biarylcarboxamide bis-aminopyrrolidine urea derived small-molecule antagonists of the melanin-concentrating hormone receptor-1 (MCH-R1).
• Structure-activity relationship of a series of cyclohexylpiperidines bearing an amide side chain as antagonists of the human melanocortin-4 receptor.
• Synthesis of functionalized acetophenones as protein tyrosine phosphatase 1B inhibitors.
• 1-Amino-1,2,3,4-tetrahydronaphthalene-2-carboxylic acid as a Tic mimetic: application in the synthesis of potent human melanocortin-4 receptor selective agonists.
• GH-releasing peptides improve cardiac dysfunction and cachexia and suppress stress-related hormones and cardiomyocyte apoptosis in rats with heart failure.
• Insulin resistance is a cause of steatosis and fibrosis progression in chronic hepatitis C.
• 6-Aryl-4-methylsulfanyl-2H-pyran-2-one-3-carbonitriles as PPAR-gamma activators.
• Discovery and SAR of 4-amino-2-biarylbutylurea MCH 1 receptor antagonists through solid-phase parallel synthesis.
• A pilot randomized controlled trial of renal protection with pioglitazone in diabetic nephropathy.
• Effect of orlistat on weight and body composition in obese adolescents: a randomized controlled trial.
• Relaxin regulates collagen overproduction associated with experimental progressive renal fibrosis.
• Expression of gremlin, a bone morphogenetic protein antagonist, in human diabetic nephropathy.
• A potency assay for a replication incompetent adenovirus type 5 carrying a human fgf-4 gene.
• Substitution of nevirapine or efavirenz for protease inhibitor versus lipid-lowering therapy for the management of dyslipidaemia.
• Phosphorylated heat shock protein 27 is involved in enhanced heart tolerance to ischemia in short-term type 1 diabetic rats.
• Efficacy of ACE-inhibitor therapy on renal disease in glycogen storage disease type 1: a multicentre retrospective study.
• Use of bivalirudin during percutaneous coronary intervention in patients with diabetes mellitus: an analysis from the randomized evaluation in percutaneous coronary intervention linking angiomax to reduced clinical events (REPLACE)-2 trial.
• Effect of sildenafil citrate and a nitric oxide donating sildenafil derivative, NCX 911, on cavernosal relaxation and superoxide formation in hypercholesterolaemic rabbits.
• Combined genetic and chemical capsid modifications enable flexible and efficient de- and retargeting of adenovirus vectors.
• Nitric oxide induces osteoblast apoptosis through a mitochondria-dependent pathway.
• Protein phosphatase 2A regulates estrogen receptor alpha (ER) expression through modulation of ER mRNA stability.
• A novel pathophysiological mechanism for osteoporosis suggested by an in vivo gene expression study of circulating monocytes.
• Fas binding to calmodulin regulates apoptosis in osteoclasts.
• Fat apoptosis through targeted activation of caspase 8: a new mouse model of inducible and reversible lipoatrophy.
• Steady-state pharmacokinetics of a novel extended-release metformin formulation.
• Identification of N-arachidonylglycine, U18666A, and 4-androstene-3,17-dione as novel insulin Secretagogues.
• Regenerative and therapeutic effects of heparin-binding epidermal growth factor-like growth factor on diabetes by gene transduction through retrograde pancreatic duct injection of adenovirus vector.
• Design and evaluation of compound metformin/glipizide elementary osmotic pump tablets.
• High glucose-induced apoptosis in human vascular endothelial cells is mediated through NF-kappaB and c-Jun NH2-terminal kinase pathway and prevented by PI3K/Akt/eNOS pathway.
• Zonisamide in the treatment of painful diabetic neuropathy: a randomized, double-blind, placebo-controlled pilot study.
• Transgenic expression of dominant-negative Fas-associated death domain protein in beta cells protects against Fas ligand-induced apoptosis and reduces spontaneous diabetes in nonobese diabetic mice.
• Insulin needs after CD3-antibody therapy in new-onset type 1 diabetes.
• Cardiac metallothionein synthesis in streptozotocin-induced diabetic mice, and its protection against diabetes-induced cardiac injury.
• Design and synthesis of alpha-aryloxyphenylacetic acid derivatives: a novel class of PPARalpha/gamma dual agonists with potent antihyperglycemic and lipid modulating activity.
• Microalbuminuria as a marker of cardiovascular risk in patients with type 2 diabetes.
• Identification of 4-methyl-1,2,3,4,10,10a-hexahydropyrazino[1,2-a]indoles as 5-HT2C receptor agonists.
• Dibenzodioxocinones--a new class of CETP inhibitors.
• Streptozotocin-induced diabetic nephropathy in rats: the role of inflammatory cytokines.
• Metabolic effects of pioglitazone in combination with insulin in patients with type 2 diabetes mellitus whose disease is not adequately controlled with insulin therapy: results of a six-month, randomized, double-blind, prospective, multicenter, parallel-group study.
• Localized gene expression following administration of adeno-associated viral vectors via pancreatic ducts.
• A preliminary study of the metabolic stability of a series of benzoxazinone derivatives as potent neuropeptide Y5 antagonists.
• Discovery and activity of (1R,4S,6R)-N-[(1R)-2-[4-cyclohexyl-4-[[(1,1-dimethylethyl)amino]carbonyl]-1-piperidinyl]-1-[(4-fluorophenyl)methyl]-2-oxoethyl]-2-methyl-2-azabicyclo[2.2.2]octane-6-carboxamide (3, RY764), a potent and selective melanocortin subtype-4 receptor agonist.
• P2-P3 conformationally constrained ketoamide-based inhibitors of cathepsin K.
• Socs1 deficiency enhances hepatic insulin signaling.
• Autocrine action of adiponectin on human fat cells prevents the release of insulin resistance-inducing factors.
• Heparanase-1 gene expression and regulation by high glucose in renal epithelial cells: a potential role in the pathogenesis of proteinuria in diabetic patients.
• Metformin prevents high-glucose-induced endothelial cell death through a mitochondrial permeability transition-dependent process.
• Rosiglitazone improves glomerular hyperfiltration, renal endothelial dysfunction, and microalbuminuria of incipient diabetic nephropathy in patients.
• Tempol reduces oxidative stress, improves insulin sensitivity, decreases renal dopamine D1 receptor hyperphosphorylation, and restores D1 receptor-G-protein coupling and function in obese Zucker rats.
• Signaling pathways involved in human vascular smooth muscle cell proliferation and matrix metalloproteinase-2 expression induced by leptin: inhibitory effect of metformin.
• Clinical outcomes in antihypertensive treatment of type 2 diabetes, impaired fasting glucose concentration, and normoglycemia: Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT).
• Effects of different blood pressure-lowering regimens on major cardiovascular events in individuals with and without diabetes mellitus: results of prospectively designed overviews of randomized trials.
• Use of inhaled insulin in a basal/bolus insulin regimen in type 1 diabetic subjects: a 6-month, randomized, comparative trial.
• Insulin-sensitizing antihyperglycemic drugs and mortality after acute myocardial infarction: insights from the National Heart Care Project.
• Guidelines for the management of osteoporosis: the present and the future.
• Two-dimensional fluorescence difference gel electrophoresis analysis of the urine proteome in human diabetic nephropathy.
• Involvement of inflammation, degradation, and apoptosis in a mouse model of glaucoma.
• The changing epidemiology of diabetic microangiopathy in type 1 diabetes.
• Osteoporosis in experimental postmenopausal polyarthritis: the relative contributions of estrogen deficiency and inflammation.
• Novel antiglaucoma prodrugs and codrugs of ethacrynic acid.
• Renal tissue factor expression is increased in streptozotocin-induced diabetic mice.
• Curcumin attenuates diet-induced hypercholesterolemia in rats.
• Clinical evidence for the safety of GAD65 immunomodulation in adult-onset autoimmune diabetes.
• Erythropoietin attenuated high glucose-induced apoptosis in cultured human aortic endothelial cells.
• Contribution of site-specific PEGylation to the dipeptidyl peptidase IV stability of glucose-dependent insulinotropic polypeptide.
• Synthesis and evaluation of photolabile insulin prodrugs.
• Synthesis of long-chain amide analogs of the cannabinoid CB1 receptor antagonist N-(piperidinyl)-5-(4-chlorophenyl)-1-(2,4-dichlorophenyl)-4-methyl-1H-pyrazole-3-carboxamide (SR141716) with unique binding selectivities and pharmacological activities.
• Protective role for cytosolic phospholipase A2alpha in autoimmune diabetes of mice.
• A new retinoid-like compound that activates peroxisome proliferator-activated receptors and lowers blood glucose in diabetic mice.
• Regulation of monocyte chemoattractant protein 1 (MCP-1) release by explants of human visceral adipose tissue.
• Changes in aortic endothelial gene expressions and relaxation responses following chronic short-term insulin treatment in diabetic rats.
• Atorvastatin induces insulin sensitization in Zucker lean and fatty rats.
• Effects of a beta-blocker on bone turnover in normal postmenopausal women: a randomized controlled trial.
• Circulating androgen levels and self-reported sexual function in women.
• Adamantyl cannabinoids: a novel class of cannabinergic ligands.
• Efficacy of risedronate in men with primary and secondary osteoporosis: results of a 1-year study.
• Tesaglitazar, a novel dual peroxisome proliferator-activated receptor alpha/gamma agonist, dose-dependently improves the metabolic abnormalities associated with insulin resistance in a non-diabetic population.
• Lead optimization of 4-(dimethylamino)quinazolines, potent and selective antagonists for the melanin-concentrating hormone receptor 1.
• Tungstate decreases weight gain and adiposity in obese rats through increased thermogenesis and lipid oxidation.
• A new selective estrogen receptor modulator with potent uterine antagonist activity, agonist activity in bone, and minimal ovarian stimulation.
• Adipose tissue transplantation protects ob/ob mice from obesity, normalizes insulin sensitivity and restores fertility.
• IL-4 inhibits bone-resorbing activity of mature osteoclasts by affecting NF-kappa B and Ca2+ signaling.
• Selective inhibition of Fcepsilon RI-mediated mast cell activation by a truncated variant of Cbl-b related to the rat model of type 1 diabetes mellitus.
• Oral salmon calcitonin induced suppression of urinary collagen type II degradation in postmenopausal women: a new potential treatment of osteoarthritis.
• Design and syntheses of melanocortin subtype-4 receptor agonists. Part 2: discovery of the dihydropyridazinone motif.
• PPARgamma regulates adipocyte cholesterol metabolism via oxidized LDL receptor 1.
• Monthly oral ibandronate therapy in postmenopausal osteoporosis: 1-year results from the MOBILE study.
• An in vivo model to study osteogenic gene regulation: targeting an avian retroviral receptor (TVA) to bone with the bone sialoprotein (BSP) promoter.
• Effects of S21403 (mitiglinide) on postprandial generation of oxidative stress and inflammation in type 2 diabetic patients.
• The CB1 receptor antagonist rimonabant reverses the diet-induced obesity phenotype through the regulation of lipolysis and energy balance.
• Insulin resistance in cognitive impairment: the InCHIANTI study.
• Amelioration of diabetic dyslipidemia by macrocyclic binuclear oxovanadium complex on streptozotocin induced diabetic rats.
• Tissue-specific expression and dimerization of the endoplasmic reticulum oxidoreductase Ero1beta.
• Gas6 induces Akt/mTOR-mediated mesangial hypertrophy in diabetic nephropathy.
• A novel protein kinase C alpha-dependent signal to ERK1/2 activated by alphaVbeta3 integrin in osteoclasts and in Chinese hamster ovary (CHO) cells.
• Influence of atorvastatin on apolipoprotein E and AI kinetics in patients with type 2 diabetes.
• The neuroprotection of insulin on ischemic brain injury in rat hippocampus through negative regulation of JNK signaling pathway by PI3K/Akt activation.
• Modulation of angiogenesis during adipose tissue development in murine models of obesity.
• Rosiglitazone attenuates atherosclerosis in a model of insulin insufficiency independent of its metabolic effects.
• HMG-CoA reductase inhibitors suppress the development and progression of carotid artery intimal-medial thickening in hypercholesterolemic type 2 diabetic patients.
• Metabolic syndrome and risk of cardiovascular events after myocardial infarction.
• Up-regulated expression of neuronal nitric oxide synthase in experimental diabetic retina.
• Mature adipocytes and perivascular adipose tissue stimulate vascular smooth muscle cell proliferation: effects of aging and obesity.
• Active metabolite of GLP-1 mediates myocardial glucose uptake and improves left ventricular performance in conscious dogs with dilated cardiomyopathy.
• Impairment of cardiac function in hypertensive patients with Type 2 diabetes: a LIFE study.
• Effects of liraglutide (NN2211), a long-acting GLP-1 analogue, on glycaemic control and bodyweight in subjects with Type 2 diabetes.
• The effect of manipulation of basal pulsatile insulin on insulin action in Type 2 diabetes.
• Clustering of protective factors for glucose intolerance and insulin resistance: a cross-sectional study.
• Long-term effects of pioglitazone and metformin on insulin sensitivity in patients with Type 2 diabetes mellitus.
• Stat4-null non-obese diabetic mice: protection from diabetes and experimental allergic encephalomyelitis, but with concomitant epitope spread.
• Acute and chronic effects of the incretin enhancer vildagliptin in insulin-resistant rats.
• Insulin resistance and risk of congestive heart failure.
• Antigen-based therapies using ignored determinants of beta cell antigens can more effectively inhibit late-stage autoimmune disease in diabetes-prone mice.
• Serum retinol binding protein 4 contributes to insulin resistance in obesity and type 2 diabetes.
• Endothelin A antagonist LU-135252 and trandolapril in the treatment of the Cohen-Rosenthal diabetic hypertensive rat.
• Prevention of oxidative stress by adenoviral overexpression of glutathione-related enzymes in pancreatic islets.
• Pathological roles of advanced glycation end product receptors SR-A and CD36.
• Synthesis and in vivo evaluation of a novel peripheral benzodiazepine receptor PET radioligand.
• The effect of insulin deficiency on tau and neurofilament in the insulin knockout mouse.
• Ameliorating effect of FK614, a novel nonthiazolidinedione peroxisome proliferator-activated receptor gamma agonist, on insulin resistance in Zucker fatty rat.
• Adamantyl triazoles as selective inhibitors of 11beta-hydroxysteroid dehydrogenase type 1.
• Role of PYK2 in the development of obesity and insulin resistance.
• Possible role of direct Rac1-Rab7 interaction in ruffled border formation of osteoclasts.
• A novel insulin delivery algorithm in rats with type 1 diabetes: the fading memory proportional-derivative method.
• Establishment of a diabetic mouse model with progressive diabetic nephropathy.
• HST2 mediates SIR2-independent life-span extension by calorie restriction.
• The oral antidiabetic pioglitazone protects from neurodegeneration and amyotrophic lateral sclerosis-like symptoms in superoxide dismutase-G93A transgenic mice.
• Rosiglitazone protects against ischemia/reperfusion-induced leukocyte adhesion in the zucker diabetic fatty rat.
• The CREB coactivator TORC2 is a key regulator of fasting glucose metabolism.
• Cdk5-dependent regulation of glucose-stimulated insulin secretion.
• NK cells promote islet allograft tolerance via a perforin-dependent mechanism.
• Adiponectin protects against myocardial ischemia-reperfusion injury through AMPK- and COX-2-dependent mechanisms.
• Agouti-related peptide-expressing neurons are mandatory for feeding.
• IP3 receptor types 2 and 3 mediate exocrine secretion underlying energy metabolism.
• Treatment of symptomatic diabetic peripheral neuropathy with the protein kinase C beta-inhibitor ruboxistaurin mesylate during a 1-year, randomized, placebo-controlled, double-blind clinical trial.
• Biaryl diamides as potent melanin concentrating hormone receptor 1 antagonists.
• Sulfonamide chalcone as a new class of alpha-glucosidase inhibitors.
• Synthesis and ex vivo evaluation of carbon-11 labelled N-(4-methoxybenzyl)-N'-(5-nitro-1,3-thiazol-2-yl)urea ([11C]AR-A014418): a radiolabelled glycogen synthase kinase-3beta specific inhibitor for PET studies.
• In vitro aldose reductase inhibitory activity of 5-benzyl-2,4-thiazolidinediones.
• Aminopiperidine indazoles as orally efficacious melanin concentrating hormone receptor-1 antagonists.
• Randomized comparison of sirolimus-eluting stent versus standard stent for percutaneous coronary revascularization in diabetic patients: the diabetes and sirolimus-eluting stent (DIABETES) trial.
• Estimated risks for developing obesity in the Framingham Heart Study.
• Increased basal phosphorylation of detrusor smooth muscle myosin in alloxan-induced diabetic rabbit is mediated by upregulation of Rho-kinase beta and CPI-17.
• Antidiabetic potential of two novel fatty acid derivatised, N-terminally modified analogues of glucose-dependent insulinotropic polypeptide (GIP): N-AcGIP(LysPAL16) and N-AcGIP(LysPAL37).
• Apolipoprotein-mediated pathways of lipid antigen presentation.
• Sirolimus-eluting stent implantation in diabetic patients with multivessel coronary artery disease.
• Acute hyperglycemia is associated with adverse outcome after acute myocardial infarction in the coronary intervention era.
• Polymorphisms in the gene encoding angiotensin I converting enzyme 2 and diabetic nephropathy.
• Caffeine-mediated enhancement of glucocorticoid receptor activity in human osteoblastic cells.
• Vasculoprotective effect of insulin in the ischemic/reperfused canine heart: role of Akt-stimulated NO production.
• Crystallographic studies on two bioisosteric analogues, N-acetyl-beta-D-glucopyranosylamine and N-trifluoroacetyl-beta-D-glucopyranosylamine, potent inhibitors of muscle glycogen phosphorylase.
• Momordin I, an inhibitor of AP-1, suppressed osteoclastogenesis through inhibition of NF-kappaB and AP-1 and also reduced osteoclast activity and survival.
• Structural basis for the GSK-3beta binding affinity and selectivity against CDK-2 of 1-(4-aminofurazan-3yl)-5-dialkylaminomethyl-1H-[1,2,3] triazole-4-carboxylic acid derivatives.
• Impact of treatment of coronary artery disease with sirolimus-eluting stents on outcomes of diabetic and nondiabetic patients.
• Incidence of end-stage renal disease in patients with type 1 diabetes.
• Effects of Brx-019 (acetic acid 3,6a,9-triacetoxy-6,6a,7, 11b-tetrahydro-indeno [2,1-c] chromen-10-yl ester), a Brazilin derivative, on T cell-mediated immune responses in multiple low dose streptozotocin-induced diabetic C57BL/6 male mice.
• Molecular docking and 3D-QSAR on 2-(oxalylamino) benzoic acid and its analogues as protein tyrosine phosphatase 1B inhibitors.
• Inhaled insulin improves glycemic control when substituted for or added to oral combination therapy in type 2 diabetes: a randomized, controlled trial.
• Exenatide versus insulin glargine in patients with suboptimally controlled type 2 diabetes: a randomized trial.
• Endothelial dysfunction in the streptozotocin-induced diabetic apoE-deficient mouse.
• Erythromycin ameliorates renal injury via anti-inflammatory effects in experimental diabetic rats.
• Evidence that the 11 beta-hydroxysteroid dehydrogenase (11 beta-HSD1) is regulated by pentose pathway flux. Studies in rat adipocytes and microsomes.
• Heme oxygenase 1 (HO-1) regulates osteoclastogenesis and bone resorption.
• Effect of weight loss on blood pressure, arterial compliance, and insulin resistance in normotensive obese subjects.
• Glucose is a key metabolic regulator of osteoclasts; glucose stimulated increases in ATP/ADP ratio and calmodulin kinase II activity.
• Combination teriparatide and raloxifene therapy for postmenopausal osteoporosis: results from a 6-month double-blind placebo-controlled trial.
• Relationship between osteoporosis and cardiovascular disease in postmenopausal women.
• VEGF improves, whereas sFlt1 inhibits, BMP2-induced bone formation and bone healing through modulation of angiogenesis.
• InDuo, a novel combined insulin injection and blood glucose monitoring device - effective and save as other devices, and patient preference.
• Genistein, EGCG, and capsaicin inhibit adipocyte differentiation process via activating AMP-activated protein kinase.
• Discovery, SAR, and X-ray structure of novel biaryl-based dipeptidyl peptidase IV inhibitors.
• Increased prevalence of third-degree atrioventricular block in patients with type II diabetes mellitus.
• Inhibition of histone deacetylase suppresses osteoclastogenesis and bone destruction by inducing IFN-beta production.
• Protection against osteoporosis by active immunization with TRANCE/RANKL displayed on virus-like particles.
• Metabolic syndrome, endothelial dysfunction, and erectile dysfunction: association and management.
• Endothelin antagonism prevents early EGFR transactivation but not increased matrix metalloproteinase activity in diabetes.
• Obesity, peroxisome proliferator-activated receptor, and atherosclerosis in type 2 diabetes.
• Effect of muraglitazar on death and major adverse cardiovascular events in patients with type 2 diabetes mellitus.
• Obestatin, a peptide encoded by the ghrelin gene, opposes ghrelin's effects on food intake.
• Design, synthesis, and evaluation of 2-alkoxydihydrocinnamates as PPAR agonists.
• Aplysamine-1 and related analogs as histamine H3 receptor antagonists.
• Substituted 4-hydroxyphenyl sulfonamides as pathway-selective estrogen receptor ligands.
• A free radical scavenger but not FGF-2-mediated angiogenic therapy rescues myonephropathic metabolic syndrome in severe hindlimb ischemia.
• The effect of short-contact topical tretinoin therapy fo